A detailed history of Vident Advisory, LLC transactions in United Therapeutics Corp stock. As of the latest transaction made, Vident Advisory, LLC holds 6,901 shares of UTHR stock, worth $2.45 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
6,901
Previous 5,095 35.45%
Holding current value
$2.45 Million
Previous $1.17 Billion 87.83%
% of portfolio
0.06%
Previous 0.02%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$228.26 - $319.04 $412,237 - $576,186
1,806 Added 35.45%
6,901 $2.2 Billion
Q1 2024

May 14, 2024

BUY
$210.76 - $249.51 $120,765 - $142,969
573 Added 12.67%
5,095 $1.17 Billion
Q4 2023

Feb 14, 2024

BUY
$214.88 - $256.94 $390,651 - $467,116
1,818 Added 67.23%
4,522 $994 Million
Q3 2023

Feb 21, 2024

SELL
$211.82 - $248.24 $385,088 - $451,300
-1,818 Reduced 40.2%
2,704 $611 Million
Q3 2023

Nov 14, 2023

BUY
$211.82 - $248.24 $572,761 - $671,240
2,704 New
2,704 $611 Million

Others Institutions Holding UTHR

About UNITED THERAPEUTICS Corp


  • Ticker UTHR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,516,300
  • Market Cap $16.2B
  • Description
  • United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...
More about UTHR
Track This Portfolio

Track Vident Advisory, LLC Portfolio

Follow Vident Advisory, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vident Advisory, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Vident Advisory, LLC with notifications on news.